FDA requests feedback on patient-level data access for regulatory review of RWE

The US Food and Drug Administration is seeking input on challenges in submitting patient-level real-world data for regulatory review. The consultation addresses data ownership, privacy, technical infrastructure and data-use agreements, with responses intended to inform policy development and support the agency’s use of real-world evidence in assessing drugs and biological products.
The Baseline
- The FDA is seeking solutions to barriers affecting patient-level data access in submissions containing RWD and RWE.
- The request covers data sharing, retention and independent review, alongside privacy considerations and legal obligations.
- Industry, technology providers, researchers and patient advocates are invited to comment by January 11, 2027.
The FDA has announced a request for information on access to patient-level data underpinning real-world evidence (RWE) in marketing applications for drugs and biological products. Although submissions containing real-world data (RWD) and RWE are increasing, the Agency reports continuing difficulties in obtaining the information needed to independently review and verify study findings.
“Access to patient-level data remains a significant challenge in advancing the use of RWE in regulatory decision-making,” explained Marie Bradley, Acting Director of FDA’s Division of Real-World Evidence Analytics. “This is a challenge I have been closely engaged with at FDA, and I am pleased to share that CDER and CBER are issuing a Request for Information (RFI) seeking innovative solutions from stakeholders to address these barriers.”
The request addresses concerns regarding patient-level data access at the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), inviting input from pharmaceutical companies, health information technology vendors, academic medical centers, electronic data capture providers and patient advocates.
While patient-level data are routinely submitted for clinical trials to support the FDA’s independent analyses, sponsors must also ensure they can submit patient-level RWD analyzed in clinical studies included in marketing applications when required under existing regulations. Where another organization controls the data, sponsors should establish agreements enabling relevant information to be provided to FDA and source data to be available for inspection, as applicable.
As FDA explains in the notice, “Frequently, sponsors do not own the RWD used in studies submitted to FDA and, therefore, lack authorization to submit patient-level information to the Agency.” Privacy considerations can further complicate access, particularly when transferring data across jurisdictions, including from the European Union.
Where appropriate justification exists, third-party providers can submit data directly to the FDA through existing pathways, including a pre-investigational new drug application or a Type V drug master file, with authorization allowing the agency to reference the information in reviewing a sponsor’s application. However, FDA does not currently accept links to external databases for these submissions.
Data-use agreements can create further barriers where contractual terms conflict with the FDA’s legal responsibilities, including requirements to destroy data that may be incompatible with federal recordkeeping obligations. Restrictions on access or sharing may similarly conflict with obligations to preserve the regulatory record or meet disclosure requirements.
Even where submission is authorized, real-world datasets containing longitudinal records, imaging or multi-omics information can be substantially larger than conventional clinical trial datasets, creating difficulties for transfer, storage and processing within the FDA’s infrastructure.
The consultation seeks solutions to these contractual and technical challenges, including approaches supporting data receipt, retention, interoperability and independent review, alongside opportunities for the FDA to collaborate with external organizations.
Through the consultation, the FDA aims to assess available solutions and emerging approaches, including factors that could support or hinder their implementation. Responses will inform strategic planning and policy development for RWD and RWE, identify opportunities for collaboration and support modernization of the agency’s information technology capabilities, while maintaining patient privacy protections and data stewardship.
Stakeholders can submit comments through Regulations.gov until January 11, 2027.
| Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox. |